🇺🇸 FDA
Pipeline program

XL092, XL092, XL092, XL092, Belzutifan

MK-3475-03C

Phase 2 small_molecule active

Quick answer

XL092, XL092, XL092, XL092, Belzutifan for Clear cell renal cell carcinoma is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Clear cell renal cell carcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials